Source: Rhythm Biosciences
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Rhythm Biosciences’ (RHY) share price more than doubles after securing regulatory approval for its colon cancer detection blood test in the UK
  • The UKCA mark certification has been granted for ColoSTAT – an affordable and user-friendly blood test designed to detect colorectal cancer
  • With this certification, Rhythm can market and sell ColoSTAT within the United Kingdom
  • Rhythm says this regulatory milestone is a crucial step in its strategic plan for commercialisation and market entry, opening up a customer market of around 24 million individuals
  • RHY shares were up 103 per cent, trading at 71 cents at 1:45 pm AEST

Rhythm Biosciences’ (RHY) share price has more than doubled, following the regulatory approval of its colon cancer detection blood test in the United Kingdom.

The company has been granted UK conformity assessment (UKCA) mark certification for ColoSTAT, a cost-effective and user-friendly blood test designed to detect colorectal cancer.

This certification now permits Rhythm to market and sell ColoSTAT within the United Kingdom.

Introduced as the new mandatory product marking in the UK post-Brexit, the UKCA mark has replaced the previous CE mark for most products.

According to Rhythm Biosciences, obtaining this certification is a vital milestone in its strategic plan for commercialisation and market entry.

The company estimates the UK customer market for ColoSTAT encompasses a screening population of approximately 24 million individuals.

“The achievement of this regulatory milestone continues to validate our commercial pathway into global markets, with the UK alone representing an addressable population of approximately 24 million people,” Rhythm Chief Commercial Officer Elena Deak said.

“Importantly, over time we expect the market size to continue expanding, as various bodies encourage earlier age screening.”

Rhythm Biosciences anticipates further progress in its UK market entry by the end of the current calendar year.

RHY shares were up 103 per cent, trading at 71 cents at 1:45 pm AEST.

RHY by the numbers
More From The Market Online
The Market Online Video

ASX Market Close: Bourse finishes week on a high as Wisetech pummeled | November 22, 2024

The ASX200 closed up 0.85% at 8,393 points. Economists increasingly expect interest rates in Australia won’t…
The Market Online Video

HotCopper Highlights: Your most watched stocks for Week 47, 2024

In this segment we’ll look at the top stocks HotCopper users have been watching, and discussing,…
Nuclear explosion mushroom cloud concept

Week 47 Wrap: HotCopper users’ most watched; Brent lifts on Putin’s scary letter; RFK dents CSL

Welcome to the end of another week. Let's start with what HotCopper users have been watching…
Dale Gillham's photo, and wording 'Words from Wealth Within's Chief Analyst Dale Gillham.

Dale Gillham’s weekly wrap: Sigma-Chemist Warehouse merger creates pharma powerhouse

The $8.8 billion dollar merger between Sigma Healthcare and Chemist Warehouse is poised to reshape the Australian pharmacy landscape, consolidating power in th…